Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.» Read More
LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.
July 23- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.
*Dow, S&P 500 may come off fourth month of gains. *VIX near multi-month lows, may be sign of complacency. NEW YORK, June 2- U.S. stock index futures pointed to a flat open on Monday, with investors finding few reasons to keep pushing shares higher, with the Dow and S&P 500 at record levels.
Friday's midday movers:
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
Feb 12- U.S. health regulators on Wednesday approved the Johnson& Johnson and Pharmacyclics Inc cancer drug Imbruvica to treat chronic lymphocytic leukemia, a slowly progressing form of blood cancer.
Feb 12- U.S. health regulators on Wednesday approved the Johnson& Johnson and Pharmacyclics Inc cancer drug Imbruvica to treat chronic lymphocytic leukemia, a slowly progressing form of blood cancer. The Food and Drug Administration decision marks the second approval recently for the medicine, known chemically as ibrutinib.
Some of Tuesday's midday movers:
Some of the names on the move ahead of the open.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
"Mad Money" host Jim Cramer made calls on stocks viewers asked about.
Cramer wants you to know about the company behind this potential breakthrough cancer drug.
The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.
TheStreet.com details the 10 best-performing biopharmaceutical stocks of 2012 and their outlook for 2013.
Jim Cramer’s researcher, Nicole Urken, reiterates the importance of assessing risk when speculating.
Find out which second-quarter top performer got the most votes.
Tell Cramer which second-quarter top performer is your All-Star!
Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.
For the second time in two weeks, an op-ed item appears in The Wall Street Journal today calling out the FDA for its record on timely approval of cancer drugs.